Literature DB >> 1540977

Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

E C De Boer1, W H De Jong, P A Steerenberg, L A Aarden, E Tetteroo, E R De Groot, A P Van der Meijden, P D Vegt, F M Debruyne, E J Ruitenberg.   

Abstract

To study the local immunological effects of intravesical bacillus Calmette-Guérin (BCG) therapy in superficial bladder cancer patients, the production of interleukin-1 (IL-1), IL-2, IL-6, tumour necrosis factor alpha (TNF alpha), and interferon gamma (IFN gamma) was investigated in the urine. Urine specimens were collected during the six weekly BCG instillations, before instillation, and 2, 4, 6, 8, and 24 h thereafter. Results were standardized to urine creatinine. In general, the concentration of IL-1 increased markedly during the first three BCG instillations, reaching a plateau from instillations 3 to 6. IL-2 was not detected after the first BCG instillation, but from the second instillation onwards the mean IL-2 concentration increased rapidly. With respect to IL-6, patients had relatively high levels in the urine after the first BCG instillation. A relatively moderate increase of the IL-6 concentration was observed during the following weeks. Like IL-2, TNF alpha was only detected after repeated BCG instillations. Generally the highest TNF levels were found after BCG instillation 5. The presence of IFN gamma could not be demonstrated. With respect to the occurrence of the cytokines during the first 24 h after the BCG instillation, TNF, IL-2, and IL-6 were detectable 2 h after the instillation. In contrast, IL-1 seemed to appear later, i.e. from 4 h onwards. TNF decreased most rapidly; it was nearly absent in 6-h samples. Generally IL-2 was not detectable in the 8-h samples, whereas IL-1 and IL-6 were present up to 8 h after instillation of BCG. The presence of TNF was found less frequently than the presence of IL-1, IL-2, and IL-6. Neutralization experiments indicated that most of the IL-1 present in the urine after BCG treatment was IL-1 alpha. In conclusion, activation of BCG-specific T cells was indicated by the detection of IL-2. The presence of IL-1, IL-6, and TNF alpha might suggest activation of macrophages by intravesically administered BCG, although production by other cell types cannot be excluded. It is suggested that these cytokines, in combination with the leucocytes that are known to be recruited to the bladder in reaction to the BCG treatment, may play an important role in the antitumour activity of BCG against bladder cancer. For monitoring purposes, collection of urine might be performed during the first 6 h after BCG instillations 4-6.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540977     DOI: 10.1007/bf01741551

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  45 in total

Review 1.  BCG in the treatment of bladder cancer: state of the art.

Authors:  A Morales
Journal:  Prog Clin Biol Res       Date:  1989

2.  Local immune responses after intravesical BCG treatment for carcinoma in situ.

Authors:  M I el-Demiry; G Smith; A W Ritchie; K James; J A Cumming; T B Hargreave; G D Chisholm
Journal:  Br J Urol       Date:  1987-12

3.  Molecular cloning and expression of hybridoma growth factor in Escherichia coli.

Authors:  J P Brakenhoff; E R de Groot; R F Evers; H Pannekoek; L A Aarden
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

4.  Secretion of interleukin-6 (IL-6) by human monocytes stimulated by muramyl dipeptide and tumour necrosis factor alpha.

Authors:  J Sancéau; R Falcoff; F Beranger; D B Carter; J Wietzerbin
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

5.  Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability.

Authors:  J M Mullin; K V Snock
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

6.  Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.

Authors:  E C de Boer; W H de Jong; A P van der Meijden; P A Steerenberg; F Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1991

7.  Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.

Authors:  A Böhle; J Gerdes; A J Ulmer; A G Hofstetter; H D Flad
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

8.  Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.

Authors:  W H De Jong; E C De Boer; A P Van der Meijden; P Vegt; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

9.  Interleukin 1 activity in normal human urine.

Authors:  E S Kimball; S F Pickeral; J J Oppenheim; J L Rossio
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

10.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

View more
  48 in total

Review 1.  Non-specific immunotherapy with bacille Calmette-Guérin (BCG).

Authors:  A P van der Meijden
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

2.  Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response.

Authors:  Romulus Breban; Aurelie Bisiaux; Claire Biot; Cyrill Rentsch; Philippe Bousso; Matthew L Albert
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 3.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

Review 4.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

5.  Fibroblast ERα promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment.

Authors:  Chiuan-Ren Yeh; Iawen Hsu; Wenbin Song; Hongchiang Chang; Hiroshi Miyamoto; Guang-Qian Xiao; Lei Li; Shuyuan Yeh
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

6.  Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer.

Authors:  K Taniguchi; S Koga; M Nishikido; S Yamashita; T Sakuragi; H Kanetake; Y Saito
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

7.  Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder.

Authors:  Chang-Ho Ryan Choi; Sang Oh Lee; Geoff Smith
Journal:  BMJ Case Rep       Date:  2014-05-08

8.  [Immunostimulatory CpG oligodeoxynucleotides (CpG-ODN) in an orthotopic murine transitional cell carcinoma (TCC) model. Effect on local cytokine expression].

Authors:  P J Olbert; A J Schrader; R Hofmann; A Hegele
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

9.  Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.

Authors:  E C de Boer; T M De Reijke; D H Schamhart; P C Vos; K H Kurth
Journal:  Urol Res       Date:  1993

10.  Study of recombinant human IFN-α-2b bacilli calmette-guerin activated killer cells and against bladder cancer cell in vitro.

Authors:  Xiaodong Fan; Ruifa Han
Journal:  Front Med China       Date:  2007-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.